Nine-time Grand Slam champion Monica Seles is using her popularity and platform to shed light on a rare chronic neuromuscular condition that has changed her life. Myasthenia Gravis.

In an interview with Good Morning America on Tuesday, the former World No. 1 revealed for the first time that she was diagnosed three years ago with myasthenia gravis, or MG, an autoimmune disease that causes muscle weakness.

"It was 30 years ago that I came back to the [U.S.] Open ... It was like a reset, and this was one of the reasons I decided to go public with my myasthenia gravis," Seles said. "It’s been a huge reset not just in my professional life as a tennis player, but also in my personal life."

Seles, who last played professionally in 2003 and officially retired in 2008, said she hopes her story will help others who may be struggling with unexplained symptoms.

Also Read: Experts Warn Against The Unique Symptoms Of 'Stratus' Covid Strain That Has Infected A Large UK Population; Can It Evade Antibodies?

Recognizing the Signs

The 51-year-old said her training as a professional athlete helped her notice early changes in her body.

"I started experiencing these symptoms of extreme leg weakness, arm weakness, double vision. So I realized, ‘This is very unusual,’" she explained. "Once I was diagnosed, it was like a relief, but also it was a challenge."

Travel, once routine during her tennis career, has become more complicated. "Even coming here today, in the old days, traveling would be a no-brainer. Now I had to get packing tips. I had to learn a new way to live with MG," she said.

Speaking Out to Help Others

Seles admitted she had never heard of myasthenia gravis before her diagnosis. "I had no clue what it was. I had a hard time pronouncing it," she said with a smile.

She hopes that talking about her experience will encourage people to seek medical advice if they notice changes in their health.

"It’s been a very challenging time dealing with it," she added. "But knowing there’s hope out there and a great community has helped me tremendously."

Her message to others: "Advocate for yourself and know your symptoms."

Also Read: Tennis Player Monica Seles Opens Up About Her Myasthenia Gravis Diagnosis

What Is Myasthenia Gravis?

According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), myasthenia gravis is a chronic neuromuscular disease that causes weakness in voluntary muscles, the muscles responsible for movements like walking, swallowing, breathing, and facial expressions.

MG occurs when the immune system mistakenly attacks healthy muscle receptors, disrupting the signals needed for muscle contraction. Johns Hopkins Medicine notes that the condition is not inherited or contagious and often develops later in life.

The disease can affect anyone, but it most commonly impacts women under 40 and men over 60. Symptoms may include:

• Drooping eyelids (ptosis) and double vision (diplopia)
• Muscle weakness that worsens with activity
• Trouble swallowing or speaking clearly
• Weakness in the arms, legs, neck, or face
• Shortness of breath in severe cases

Symptoms can vary widely between individuals. In rare situations, a myasthenic crisis may occur, affecting breathing muscles and requiring emergency medical care.

Diagnosis and Treatment

Because the symptoms of MG can resemble other health conditions, diagnosis involves a combination of physical and neurological exams, blood tests, and nerve stimulation studies.

There is currently no cure, but treatments can help manage symptoms and improve quality of life. These may include medications that enhance communication between nerves and muscles, immunosuppressive drugs, and in some cases, surgery to remove the thymus gland.

Temporary forms of MG can occur in newborns if a mother has the disease, but these cases usually resolve within two to three months.

Looking Ahead

While managing myasthenia gravis has brought challenges, Seles continues to find joy in life and in the sport she loves. She still follows tennis closely and is excited about the current generation of players.

"I wish I had a crystal ball," she said. "I love Coco Gauff, the electricity she brought to the U.S. Open. As a tennis fan, we just want great matches and the excitement of the fans."

By sharing her personal journey, Seles hopes to break the silence around MG and help others feel less alone. "When I got diagnosed, I wished I had heard someone talk about it. Now, I hope my story can be that for someone else."

Sick days are again piling up with a respiratory disease, not COVID-19 or the flu. This disease is most likely the one Americans have not heard of. This is HMPV or human metapneumovirus. Doctors have asked people to stay vigilant as seasonal flu virus could lead to pneumonia and bronchitis, and it is spreading in California wastewater and around the country. However, as per public health officials, there is nothing to get worried at this point.

As per the public database WasterwaterScan Dashboard, high levels of HMPV were detected across Northern California cities. The highest levels were reported in Redwood City, whereas elevated levels were found in San Francisco Bay Area and Napa's Wine Country. What's more dangerous is that this virus is without a vaccine.

The good news is that in other parts of country HMPV remains lower. However, the Centers for Disease Control and Prevention (CDC) noted that data from October 2025 shows the cases are trending up, especially during winter and spring.

Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic, as reported by The Independent said, "In the late winter, early spring, it can account for five percent to 10 percent of all the respiratory infections that we diagnose in the United States. So it's definitely out there." Experts explain that other viruses like HMPV or influenza get a chance when COVID is quieter.

Read: HMPV Virus Cases Surging In California, New Jersey: Is It Dangerous?

Virus Without A Vaccine: What Is HMPV?

HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).

HMPV most likely spreads from an infected person to others through:

• the air by coughing and sneezing
• close personal contact, such as touching or shaking hands
• touching objects or surfaces that have the viruses on them, then touching the mouth, nose, or eyes

In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.

The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:

• cough
• fever
• nasal congestion
• shortness of breath

People at risk include:

• elderly people
• children
• people with comorbidities

"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.

“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.

While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:

Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.

Why Are People Hearing About The Virus Without Vaccine Now?

The reason people have not heard about it before is because its symptoms are nearly indistinguishable from other respiratory infections, so often it could go undiagnosed. Furthermore, earlier the COVID cases and influenza cases sparked up, which deviated the attention from HMPV. Now, with the season gone, and increased awareness around respiratory illnesses, greater attention to viruses like HMPV is also paid.

One in seven Indians, or over 14 percent of the population, suffers from some form of mental health disorder. Amid an increasing treatment gap -- up to 90 percent -- seen in several states, especially in North India, the government today reiterated the plan of launching a second National Institute of Mental Health and Neurosciences (NIMHANS) in the northern states.

NIMHANS-2 was first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27, to deliver specialized care for mental health and neurological disorders in north India.

Health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.

"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.

Noting that Non-Communicable Diseases (NCDs) account for over 60 percent of deaths in the country, they added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)," among the citizens.

Need For Tertiary Neuro-psychiatric Care

To address these, the experts called for ramping up tertiary mental health institutions and expanding specialized services.

The session, moderated by Vijay Nehra, Joint Secretary, Ministry of Health and Family Welfare, highlighted that North India currently lacks adequate tertiary neuro-psychiatric care facilities. These include areas such as:

• advanced neuroimaging,
• neurocritical care,
• specialized neurological services

Further, making a virtual address at the Post-Budget Webinar, Union Health Minister JP Nadda also highlighted the government’s focus on strengthening mental healthcare services in the country.

"NIMHANS-2 will be established in North India to expand advanced clinical care, training, and research," Nadda said.

"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," he added.

Meanwhile, the experts also stressed the need to improve services in underserved and geographically remote regions, including the northeastern states, through better infrastructure, capacity building, and targeted deployment of trained mental health professionals.

They also discussed strategies for expanding advanced neuro-psychiatric care and reinforcing India’s overall mental healthcare ecosystem. They proposed:

• Adopting a hub-and-spoke model supported by digital health platforms

This would allow tertiary institutions and centers of excellence to provide technical guidance, specialist consultations, and clinical support to district hospitals and community-level health facilities.

"Such a model would strengthen referral pathways and ensure that specialized mental health services are accessible to people even in remote and rural areas," the experts said.

• Integrating services under Tele-MANAS

Both existing and upcoming campuses of NIMHANS must be integrated , as this will enable a robust nationwide tele-mental health network that ensures

• timely counselling,
• psychological support,
• specialist consultations

• Digital follow-up systems

The experts called for the seamless integration of healthcare facilities, aligned with the vision of the Ayushman Bharat Digital Mission and the ABHA ID ecosystem. This, they said, will

• enable continuity of care,
• Improve monitoring of patients,
• Lead to better clinical outcomes

• A national Brain-Mind Cloud Network

The Network proposed under the National Health Mission would connect premier institutions such as All India Institute of Medical Sciences (AIIMS), state medical colleges, and primary healthcare centers through a digitally integrated platform.

It could also facilitate

• unified mental health records,
• AI-based screening tools,
• data-driven clinical decision support systems,
• tele-neuro-psychiatric hubs at regional centers.

California and New Jersey in the US are seeing an uptick in cases of human metapneumovirus (HMPV) -- a virus with no vaccine or treatment.

According to the US Centers for Disease Control and Prevention (CDC), HMPV can cause upper and lower respiratory disease. There is currently no vaccine to prevent it, and no specific antiviral therapy to treat it.

"Most people will recover on their own," the agency noted, but advised people who get sick to drink plenty of liquids, stay home, and rest.

As per the CDC's respiratory dashboard, the cases of HMPV steadily ticked up since November 2025. It accounted for over 5 percent of positive tests the week of February 14 through February 21.

While HMPV is not a "new" virus, having first been discovered in 2001, cases haven't spiked to this level in the US since an outbreak in April 2025, USA Today reported.

The New Jersey Respiratory Surveillance Report cited that about 4 percent of residents in the state are testing positive for HMPV. The HMPV cases, accompanied by RSV, COVID, and flu cases, are surging, increasing the number of people seeking emergency medical care.

As per the public database, WastewaterScan Dashboard, HMPV is rampant in Northern California -- specifically San Francisco, Marin, Vallejo, Napa, Novato, Santa Rosa, Sacramento, and Davis, the Independent UK reported.

What Is HMPV? Is It Dangerous?

HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).

HMPV most likely spreads from an infected person to others through:

• the air by coughing and sneezing
• close personal contact, such as touching or shaking hands
• touching objects or surfaces that have the viruses on them, then touching the mouth, nose, or eyes

In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.

The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:

• cough,
• fever,
• nasal congestion,
• shortness of breath

People at risk include:

• elderly people,
• children,
• people with comorbidities

"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.

“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.

While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:

Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.